The FDA subsequently classified AOD-9604 within Category 2 of the bulk drug substance review process, and the compound was later withdrawn from that nomination in April 2026
10.3390/jcm10132773 J
Conforti FL, Sprovieri T, Mazzei R, Ungaro C, La Bella V, Tessitore A, Patitucci A, Magariello A, Gabriele AL, Tedeschi G, Simone IL, Majorana G, Valentino P, Condino F, Bono F, Monsurr MR, Muglia M, Quattrone A (2008) A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy
The rankings and reviews in this article represent the editorial opinion of the Protide Health publishing team and are not independent
Each Optic Labs BAC water vial is suitable for reconstituting multiple peptide vials over its in-use lifetime